Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. LLY
stocks logo

LLY

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
14.34B
+26.9%
5.530
+41.06%
15.38B
+34.42%
6.124
+418.99%
17.03B
+25.81%
6.852
+28.81%
Estimates Revision
The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 1.02% over the past three months. During the same period, the stock price has changed by -18.57%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.02%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.57%
In Past 3 Month
Stock Price
Go Down
down Image
-18.57%
In Past 3 Month
20 Analyst Rating
up Image0
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 983.13 USD with a low forecast of 700.00 USD and a high forecast of 1124  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
1 Hold
1 Sell
Strong Buy
up Image0
Current: 717.710
sliders
Low
700.00
Averages
983.13
High
1124
up Image0
Current: 717.710
sliders
Low
700.00
Averages
983.13
High
1124
UBS
Trung Huynh
Strong Buy
Maintains
$1,100 → $1,050
2025-05-02
Reason
UBS
Trung Huynh
Price Target
$1,100 → $1,050
2025-05-02
Maintains
Strong Buy
Reason
UBS analyst Trung Huynh lowered the firm's price target on Eli Lilly to $1,050 from $1,100 and keeps a Buy rating on the shares. UBS thinks the selloff is overdone in light of robust GLP franchise sales.
HSBC
Rajesh Kumar
Strong Buy
to
Sell
Downgrades
$1,150 → $700
2025-04-28
Reason
HSBC
Rajesh Kumar
Price Target
$1,150 → $700
2025-04-28
Downgrades
Strong Buy
to
Sell
Reason
Cantor Fitzgerald
Carter Gould
Buy
Initiates
$975
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
$975
2025-04-22
Initiates
Buy
Reason
Cantor Fitzgerald initiated coverage of Eli Lilly with an Overweight rating and $975 price target.
Guggenheim
Seamus Fernandez
Strong Buy
Maintains
$973 → $928
2025-04-14
Reason
Guggenheim
Seamus Fernandez
Price Target
$973 → $928
2025-04-14
Maintains
Strong Buy
Reason
Guggenheim lowered the firm's price target on Eli Lilly to $928 from $973 and keeps a Buy rating on the shares. The firm is updating its model ahead of Q1 earnings due to be reported May 1. The tirzepatide franchise remains top of mind and the current prescription trajectory suggests the firm's and consensus 2025 numbers are "comfortably achievable," the analyst tells investors in a preview.
Morgan Stanley
Terence Flynn
Buy
Maintains
$1,146 → $1,124
2025-04-09
Reason
Morgan Stanley
Terence Flynn
Price Target
$1,146 → $1,124
2025-04-09
Maintains
Buy
Reason
After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly's (LLY) branded tirzepatide and generic liraglutide, Morgan Stanley analyst Craig Hettenbach said an expanding offering could help ease some concerns over the company's target of $725M in weight loss revenue in 2025. However, margins that Hims realizes for branded tirzepatide are likely well below their compounded GLP-1 products, the analyst tells investors. The firm, which argues that the durability of personalized compounded GLP-1 and momentum in oral weight loss drugs remain the biggest factors in determining whether Hims will deliver on its revenue guidance, keeps an Equal Weight rating and $60 price target on Hims shares.
Goldman Sachs
Asad Haider
Hold
to
Strong Buy
Upgrades
$892 → $888
2025-04-08
Reason
Goldman Sachs
Asad Haider
Price Target
$892 → $888
2025-04-08
Upgrades
Hold
to
Strong Buy
Reason
Goldman Sachs upgraded Eli Lilly to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name. Following the recent selloff, Eli Lilly shares offer a "compelling entry point into the sector's premier topline grower," the analyst tells investors in a research note. The firm believes the company "will maintain its pole position" as the leader in the anti-obesity medication market, which Goldman says it set to triple in size from$28B today to $95B by 2030.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Eli Lilly and Co (LLY.N) is 30.30, compared to its 5-year average forward P/E of 39.17. For a more detailed relative valuation and DCF analysis to assess Eli Lilly and Co 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
39.17
Current PE
30.30
Overvalued PE
52.17
Undervalued PE
26.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
29.34
Current EV/EBITDA
23.03
Overvalued EV/EBITDA
37.91
Undervalued EV/EBITDA
20.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
10.41
Current PS
10.83
Overvalued PS
13.79
Undervalued PS
7.04

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 163841.95% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

LLY News & Events

Events Timeline

(ET)
2025-05-22
09:42:56
Evernorth weight loss drug price point attractive compared to Hims, says Truist
select
2025-05-22
09:39:42
Cigna's Evernorth caps monthly weight loss drug cost at $200
select
link
2025-05-21 (ET)
2025-05-21
16:23:54
Eli Lilly's Kisunla granted marketing authorization in Australia for Alzheimer's
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
05-22Newsfilter
PinnedLilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
  • Kisunla Approval in Australia: Eli Lilly's Kisunla (donanemab) has received marketing authorization from the Australian Therapeutic Goods Administration for treating mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are Apolipoprotein E ε4 heterozygotes or non-carriers. It is the first amyloid-targeting therapy registered in Australia, showing significant efficacy in slowing cognitive decline.

  • Clinical Trial Results and Safety Concerns: The approval was based on positive results from the TRAILBLAZER-ALZ 2 Phase 3 study, which demonstrated a 35% reduction in cognitive decline compared to placebo. However, the treatment can cause serious side effects, including amyloid-related imaging abnormalities (ARIA), necessitating careful monitoring during administration.

Preview
4.5
00:45 AMCNBC
The market has finally left overbought territory — and why Cramer is watching health-care stocks
  • Market Overview: Stocks showed slight gains following a sell-off, with bond yields rising due to concerns over President Trump's tax bill potentially increasing the U.S. budget deficit; the S&P 500 Oscillator has moved out of overbought territory for the first time since April.

  • Sector Focus: The health-care sector is under scrutiny as the tax bill progresses, particularly affecting companies like HCA Healthcare and Humana; tech stocks such as Apple and Nvidia are also being monitored, with Nvidia showing positive movement amid strong demand for AI projects.

Preview
5.0
00:12 AMCNBC
We’re adding to our position in this out-of-favor, high-quality drugmaker stock
  • Eli Lilly Stock Purchase: Jim Cramer's Charitable Trust is buying 10 shares of Eli Lilly, increasing its holdings to 125 shares and raising its portfolio weighting in the stock to 2.65%. The stock has recently dropped about 20% due to concerns over tariffs, drug pricing policies, and competition from Novo Nordisk.

  • Market Position and Future Outlook: Despite current challenges, Eli Lilly's stock is trading at a 52-week low, with potential for recovery as it prepares to launch both injectable and oral GLP-1 medications next year, which are expected to enhance its market share in the growing obesity treatment sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Eli Lilly and Co (LLY) stock price today?

The current price of LLY is 717.71 USD — it has decreased -1 % in the last trading day.

arrow icon

What is Eli Lilly and Co (LLY)'s business?

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

arrow icon

What is the price predicton of LLY Stock?

Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 983.13 USD with a low forecast of 700.00 USD and a high forecast of 1124 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Eli Lilly and Co (LLY)'s revenue for the last quarter?

Eli Lilly and Co revenue for the last quarter amounts to 12.73B USD, increased 45.17 % YoY.

arrow icon

What is Eli Lilly and Co (LLY)'s earnings per share (EPS) for the last quarter?

Eli Lilly and Co. EPS for the last quarter amounts to 3.06 USD, increased 23.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Eli Lilly and Co (LLY)'s fundamentals?

The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 1.02% over the past three months. During the same period, the stock price has changed by -18.57%.
arrow icon

How many employees does Eli Lilly and Co (LLY). have?

Eli Lilly and Co (LLY) has 43000 emplpoyees as of May 23 2025.

arrow icon

What is Eli Lilly and Co (LLY) market cap?

Today LLY has the market capitalization of 687.06B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free